Refferences
- Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities
from immunotherapy: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol 2017;28(suppl 4):iv119-iv142.
- Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy
for the practitioner. J Clin Oncol 2015;33(18):2092-2099.
- Villadolid J, Amin A. Immune checkpoint inhibitors in clinical
practice: update on management of immune-related toxicities. Transl
Lung Cancer Res 2015;4(5):560-575.
- Coleman L, Ko C, Dai F, et al. Inflammatory eruptions associated with
immune checkpoint inhibitor therapy: A single-institution
retrospective analysis with stratification of reactions by toxicity
and implications for management. J Am Acad Dermatol
2018;80(4):990-997.
- Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of
dermatologic toxicities from immune checkpoint blockade therapy. J
Cutan Pathol 2017;44(2):158-176.
- Shi VJ, Rodic N, Gettinger S, et al. Clinical and histologic features
of lichenoid mucocutaneous eruptions due to anti-programmed cell death
1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol
2016;152(10):1128-1136.
- Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP.
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint
antibodies. Curr Opin Oncol 2016;28(4):254-263.
- Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin
toxicities and immunotherapy. Am J Clin Dermatol 2018;19(3):345-361.
- Lomax AJ, McQuillan PA, Hall A, McArthur GA. Acute toxic epidermal
necrolysis reaction post single dose pembrolizumab with preceding
cephalosporin exposure: successful rechallange with anti-PD-1 therapy.
J Intern Med 2019;49:1051-1053.
- Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell
death-ligand 1 expression in TEN associated with nivolumab therapy. J
Cutan Pathol 2017;44:381-384.
- Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of
immune checkpoint inhibitor therapy. Clinics in Dermatol
2020;38:94-104.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and
ipilimumab or monotherapy in untreated melanoma. N Engl J Med
2015;373(1):23-34.
- Suozzi KC, Stahl M, Ko CJ, et al. Immune-related sarcoidosis observed
in combination ipilimumab and nivolumab therapy. JAAD Case Rep
2016;2(3):264-268.
- Munoz J, Guillot B, Girard C, Dereure O, Du-Thanh A. First report of
ipilimumab induced-Grover disease. Br J Dermatol 2014;171:1236-1237.
- Koelzer VH, Buser T, Willi N, et al. Grover’s-like drug eruption in a
patient with metastatic melanoma under ipilimumab therapy. J
Immunother Cancer 2016;4:47.
- Uemura M, Faisal F, Haymaker C, et al. A case report of Grover’s
disease from immunotherapy-a skin toxicity induced by inhibition of
CTLA-4 but not PD-L1. J Immunother Cancer 2016;4:55.
- Charollais R, Aubin F, Roche-Kubler B, Puzenat E. Two cases of
granuloma annulare under anti-PD1 therapy. Ann Dermatol Venereol
2018;145(2):116-119.
- Sheik S, Goddard AL, Luke JJ, et al. Drug-induced dermatomyositis
following ipilimumab therapy. JAMA Dermatol 2015;151:195-199.
- Yamaguchi Y, Abe R, Haga N, Shimizu H. A case of drug-associated
dermatomyositis following ipilimumab therapy. Eur J Dermatol
2016;26:320-326.
- Cappeli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and
sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis
2017;76:43-50.
- Coleman E, Panse G, Haldas J, Gettinger S, Leventhal JS. Pityriasis
rubra pilaris-like erythroderma in the setting of pembrolizumab
therapy responsive to acitretin. JAAD Case Rep 2018;4(7):669-671.
- Hwang SJE, Carlos G, Wakade D, Sharma R, Fernandez-Penas P.
Ipilimumab-induced acute generalized exanthematous pustulosis in a
patient with metastatic melanoma. Melanoma Res 2016;26(4):417-420.
- Page B, Borradori L, Beltraminelli H, Yawalkar N, Hunger RE. Acute
generalized exanthematous pustulosis associated with ipilimumab and
nivolumab. J Eur Acad Dermatol Venereol 2018;32(7):e256-e257.
- Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse
events and kinetics of response with ipilimumab. J Clin Oncol
2012;30(21):2691-2697.
- Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects
of the immunecheckpoint inhibitors. Curr Probl Cancer
2017;41(2):125-128.
- Tetzlaff MT, Nagarajan P, Chon S, et al. Lichenoid dermatologic
toxicity from immune checkpoint blockade therapy: A detailed
examination of the clinicopathologic features. Am J Dermatopathol
2017;39(2):121-129.
- Wang LL, Patel G, Chiesa-Fuxench ZC, et al. Timing of onset of adverse
cutaneous reactions associated with programmed cell death protein 1
inhibitor therapy. JAMA Dermatol 2018;154(9):1057-1061.
- Kato Y, Otsuka A, Miyachi Y, Kabashima K. Exacerbation of psoriasis
vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad
Dermatol Venereol 2016;30(10):e89-e91.
- Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T. Exacerbation of
psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm
Venereol 2016;96(2):259-260.
Table 1. Demographics, underlying malignancy, and immunotherapy of the
trial participants